Jaguar Health Converts Preferred Stock, Dilution Continues Amid Deep Distress

What happened

Jaguar Health announced the mandatory conversion of its Series O Convertible Preferred Stock, originally issued as a stock dividend, into common shares. This move, while reducing preferred equity liability, adds to the already massive dilution that has increased share count over 600% year-over-year. The conversion does nothing to address the company's fundamental crisis: $3.5M in cash against $36.1M in current liabilities and a looming $27M annual royalty floor starting April 2026. With quarterly revenue flat at ~$3.1M and cash burn of ~$6.1M, the company remains on a path toward either severe dilution or restructuring. The news is a routine financing maneuver, not a catalyst, and underscores the ongoing erosion of common equity value.

Implication

For long-term holders, this conversion reinforces the thesis that equity will be systematically impaired to service debt and royalty obligations. Without a major restructuring or partnership, the stock offers lottery-ticket upside with high probability of near-total loss.

Thesis delta

The thesis remains unchanged: Jaguar is a STRONG SELL. The conversion is a minor, expected step in the ongoing dilution cycle. No new information alters the bearish outlook; the key risks—cash burn, fixed royalty obligations, and stagnant revenue—remain fully intact. The only shift is a slightly larger share count, further reducing per-share value.